drugset / Trial / NCT07817251
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this clinical study is to look at the safety and tolerability of switching from semaglutide to CagriSema, for participants who have type 2 diabetes. All participants will get CagriSema, the treatment being tested. Participants will be in this clinical study for about 6 months.
Timeline
- Start
- 2026-09-16
- Primary completion
- 2027-06-09
- Completion
- 2027-07-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cagrilintide | Protein / enzyme biologic | — | Subcutaneous |
| Subject | Semaglutide | Peptide | — | Subcutaneous |